SCHEDULE: Kua Khai Loon to Hold 20.76% Stake in Cyclacel Pharma

Kua Khai Loon will beneficially own 20.76% of Cyclacel Pharmaceuticals, Inc. common stock and warrants, effective September 1, 2025.

Summary

• Kua Khai Loon will beneficially own an aggregate of 872,000 shares of Cyclacel Pharmaceuticals, Inc. common stock, representing 20.76% of the class, effective September 1, 2025.
• The beneficial ownership consists of 218,000 shares of common stock and 654,000 shares underlying three series of warrants (Series A, B, and C).
• Each of the Series A, B, and C warrants entitles the holder to purchase 218,000 shares of common stock.
• The Series A warrants have an exercise price of $7.65 per share, Series B warrants at $9.00 per share, and Series C warrants at $10.20 per share.
• All warrants have an initial exercise date of June 20, 2025, an issue date of September 1, 2025, and a termination date of June 20, 2030.
• Kua Khai Loon holds sole voting and dispositive power over all 872,000 beneficially owned shares.

Sentiment

Score: 8

Explanation: The disclosure of a substantial, forward-dated beneficial ownership stake by a single individual, including common stock and multiple series of warrants, signals strong investor confidence and a strategic long-term commitment to the company. This significant investment could be a catalyst for future growth or stability.

Positives

• A significant beneficial ownership stake of 20.76% by an individual investor, Kua Khai Loon, signals strong confidence in Cyclacel Pharmaceuticals, Inc.'s future prospects.
• The issuance of warrants provides a potential future capital infusion for the company upon their exercise, strengthening its financial position.
• The structured nature of the warrants with varying exercise prices and a five-year exercise window (until June 20, 2030) offers flexibility for both the investor and the company.

Risks

• The exercise of the warrants could lead to significant dilution for existing shareholders, increasing the total number of outstanding common shares.
• Warrant shares acquired upon exercise, if not registered and if cashless exercise is not utilized, will have restrictions on resale imposed by state and federal securities laws.

Future Outlook

The issuance of these warrants, effective September 1, 2025, indicates a future potential for capital infusion into Cyclacel Pharmaceuticals, Inc. upon their exercise. This also implies a potential increase in the company's outstanding share count over the next five years, depending on market conditions and the holder's decisions.

Industry Context

na

Stakeholder Impact

• Shareholders: Potential for future dilution if warrants are exercised, but also a signal of strong investor confidence which could positively influence stock perception.
• Company: Potential for significant capital infusion upon warrant exercise, which can support operations, research, and development.

Next Steps

• The holder, Kua Khai Loon, may exercise the Series A, B, and C warrants at any time between June 20, 2025, and June 20, 2030, potentially increasing the company's capital and outstanding shares.

Key Dates

Recommendation

A substantial, forward-dated beneficial ownership stake by a single individual, including common stock and multiple series of warrants, signals strong investor confidence and a strategic long-term commitment to the company. This significant investment could be a catalyst for future growth or stability, making the stock an attractive 'buy' for investors looking for companies with strong insider backing and future capital potential.

Keywords

Cyclacel Pharmaceuticals, Kua Khai Loon, beneficial ownership, Schedule 13G, warrants, common stock, equity investment, biotechnology, pharmaceuticals, investor stake